A Soluble BMP Antagonist Polypeptide Increases Bone Mass and Improves Bone Strength

Nicolas Solban(Harvard University), R. Scott Pearsall(Acceleron Pharma (United States)), Benjamin Umiker(Acceleron Pharma (United States)), Y. Kawamoto(Acceleron Pharma (United States)), Milton Cornwall-Brady(Massachusetts Institute of Technology), Shana Walrond(Acceleron Pharma (United States)), Dianne Sako(University of Washington), Jasbir Seehra(Acceleron Pharma (United States)), Kathryn Underwood(Toronto Metropolitan University), Travis Monnell(Acceleron Pharma (United States)), Rita M. Steeves(Acceleron Pharma (United States)), Ravi Kumar(Sardar Vallabhbhai Patel University of Agriculture & Technology), June Liu(Capital Medical University), Kathleen Tomkinson(Acceleron Pharma (United States))
Bone
March 1, 2010
10.1016/j.bone.2010.01.067
Cited by 0

Related Papers

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
|Nature|2001|484
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
|Nature|2017|348
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
|Science Translational Medicine|2020|240
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
|Proceedings of the National Academy of Sciences|2010|235
Reduced Macrophage Apoptosis Is Associated With Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor-Null Mice
|Arteriosclerosis Thrombosis and Vascular Biology|2004|219